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http://dx.doi.org/10.1016/j.jmii.2012Interleukin-12 (IL-12) is a cytokine which is secreted by activated phagocytes and dendritic
cells and promotes cell-mediated immunity to intracellular pathogens, by inducing type
1 helper T cell (TH1) responses and interferon- g (IFN- g) production. Defects in the IL-12
may cause selective susceptibility to intracellular pathogens, such as mycobacteria. We herein
report on a 13-year-old girl with defective mitogen-induced IL-12 production, who developed
intestinal tuberculosis with wide dissemination involving the lung and urinary tract. She
improved gradually, but developed terminal ileal perforation approximately 6.1 months
following initiation of anti-tuberculous treatment. The paradoxical response phenomenon
was suspected. The girl subsequently underwent surgical resection of the affected bowel
segment with a temporary double barrel stoma, and ileocolonic anastomosis was performed
after the completion of the anti-tuberculous therapy. The patient remained well, with no
evidence of recurrent tuberculosis in the past 5 years. This case illustrates the possibility of
underlying primary immunodeficiency in a patient with disseminated tuberculosis; delayed
tuberculous intestinal perforation can develop during chemotherapy for tuberculosis.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.astroenterology and Hepatology, Department of Medicine and Geriatrics, Tuen Mun Hospital, Tuen
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Primary immunodeficiency diseases are attributable to
a deficiency in cellular, humoral, or molecular functions of
the immunity systems.1 Patients with primary immunode-
ficiency diseases usually present clinically with an
increased frequency, severity, or persistence of infections,
or with an occurrence of infections which are attributable
to opportunistic pathogens. We report a patient with
defective mitogen-induced interleukin-12 (IL-12) produc-
tion, who was diagnosed with intestinal tuberculosis with
wide dissemination and who experienced free intestinal
perforation during anti-tuberculous treatment.
Case report
A 13-year-old girl was admitted to our hospital with a 2-year
history of chronic abdominal pain of increasing severity. The
pain was poorly localized, colicky in nature and partially
relieved after defecation. She had nausea, malaise, reduced
appetite with weight loss of two pounds in 2 months. Despite
regular dietary intake, she was noted to have “poor growth”
for a few years. Otherwise, her past health was unremark-
able. Her parents had consanguineous marriage and the
patient had two elder sisters aged 18 and 20 years, with good
past health. On examination, shewas pale with a bodyweight
of 27 kg (5 kg < third percentile) and had bilateral ankle
edema. Right pleural effusion and ascites were detected.
Baseline laboratory investigation was as follows:
hemoglobin Z 8.7 g/dL (normal Z 11.6e15.5); mean cell
volume Z 71.5 fL (normal Z 83e98); white blood cell
count Z 8.0/mm3 (normal Z 3.9e10.7); neutrophil Z 5.4/
mm3 (normalZ 2.1e7.8); lymphocyteZ 0.6/mm3 (normalZ
1.2e3.4); platelet count Z 387/mm3 (normal Z 152e358);
sodium Z 133 mmol/L (normal Z 136e145); pota-
ssium Z 3.6 mmol/L (normal Z 3.5e5.1); erythrocyte
sedimentation rateZ 47 mm/hour (normal< 31); c-reactive
protein Z 43.7 mg/L (normal < 8); urea Z 3.7 mmol/L
(normal Z 1.4e5.4); creatinine Z 24 umol/L (50e77);
albumin Z 13 g/L (normal Z 29e42); globulin Z 27 g/L
(normal, no reference); total bilirubinZ 9 umol/L (normalZ
5e20); alanine aminotransferase Z 12 IU/L (normal Z
5e20); alkaline phosphataseZ 85 IU/L (normalZ 50e162);
calcium Z 2.12 mmol/L (normal Z 2.10e2.55 mmol/L);
phosphate Z 0.84 mmol/L (normal Z 0.9e1.55); spot
glucoseZ 8.6 mmol/l (normal, no reference). Chest radiog-
raphy upon admission showed a right pleural effusion. Ultra-
sound (US)-guided thoracentesis with biopsy revealed
exudative lymphocytic pleural effusion, with non-specific
histology in pleural tissue. Computed tomography (CT) scan
of the thorax, abdomen and pelvis revealed that there was
bilateral pleural effusion, bowel wall thickening with
increased stranding of mesenteric fat and ascites. The liver,
spleen, pancreas, both kidneys and ureters appeared unre-
markable.Nothoracicand intra-abdominal lymphadenopathy
was demonstrated in CT imaging. A technetium-99m-labeled
human serum albumin scan showed protein leakage in the
ascending colon (Fig. 1A, 1B and 1C). Colonoscopy without
terminal ileum intubation showed multiple ulcers with
nodular edges present at the ileocecal valve and histological
examination revealed the ulcers were infiltrated byneutrophils, lymphocytes and histiocytes, with the presence
of numerous acid-fast bacilli on Ziehl-Neelsen staining
(Fig. 2A, 2B and 2C). Culture of the sputum, early morning
urine and pleural fluid subsequently yielded a positive growth
of Mycobacterium tuberculosis (MTB), which was sensitive to
isoniazid (INH), rifampicin, ethambutol, and streptomycin.
Testing forHIVantibodieswas negative. Thus, the patient had
a diagnosis of intestinal tuberculosis, causing protein-losing
enteropathy, with wide dissemination, involving the lung
and urinary system. Treatment with once daily INH 150 mg,
rifampicin 300 mg, pyrazinamide 1 g, and ethambutol 750 mg
was commenced. The anti-tuberculous drug regimen was
interrupted for 5 days because of impaired renal function,
which was thought to be due to acute tubular nephritis
caused by rifampicin, with features including: serum
creatinineZ 151 umol/L, glomerular filtration rateZ 29mL/
min/1.73m2, glycosuria, and increased urinary loss of sodium
and potassium. Anti-tuberculous treatment with INH, pyr-
azinamide, ethambutol and levofloxacin was restarted upon
normalization of the renal function. The patient’s condition
improved, with resolution of abdominal pain and pleural
effusion. One year of anti-tuberculous therapy was planned
including an initial 3 months of INH, pyrazinamide, etham-
butol and levofloxacin, followed by 9 months of INH, levo-
floxacin and ethambutol. She was evaluated for primary
immunodeficiency. The lymphocyte subset prolife was per-
formed by flow cytometry and the results were :
lymphocytesZ 644/mL (normalZ 1900e3200); B-cellsZ 86/
mL (normal Z 300e500); T-cells Z 488/mL (normal Z
1300e2200); CD4 TcellZ 375/mL (normalZ 600e1100); CD8
TcellsZ 129/mL (normalZ 500e1000); and NK cellsZ 41/mL
(normalZ 300e500). The patient had lymphopenia affecting
all lymphocyte subsets. The proliferation response of the
patient’s lymphocytes toantigen stimuli [phytohemagglutinin
(PHA), purified protein derivative (PPD) and Cryptococcus]
was suboptimal. The mitogen-stimulated cytokine profile of
the patient, performed by the Enzyme-linked immunospot
(ELISPOT) assay, revealed that PHA- and conA-stimulated IL-
12 were seriously low (Table 1). This was compatible with IL-
12 deficiency.
Eight weeks following discharge (128 days after
commencement of anti-tuberculous therapy ), the patient
presented again with acute-onset right lower quadrant
colicky pain of increasing severity and diarrhea for 3 days.
There were signs of bilateral pleural effusion, ascites and
vague non-tender right lower quadrant mass on physical
examination. Routine blood tests revealed anemia
(hemoglobin Z 6.7 g/dL), lymphopenia (0.5/mm3), and
hypoalbuminemia (albumin 11 g/L). A CT scan of the thorax
and abdomen revealed similar findings as compared with
the previous imaging. The peritoneal fluid by US-guided
diagnostic paracentesis showed the presence of viable
acid-fast bacilli, without emergence of a resistant strain.
The sputum and early morning urine had no growth of MTB.
The working diagnosis was the underlying defective
mitogen-induced IL-12 production, which made the
disseminated MTB infection not well-controlled. The anti-
tuberculous regimen was intensified to include intrave-
nous amikacin and levofloxacin was switched from the oral
to the intravenous route. Her clinical condition gradually
improved. About 4 weeks afterwards (182 days after the
anti-tuberculous therapy had been started), the patient
Figure 1. (A) Mildly focal increased tracer activity at the right lower quadrant of the abdomen was seen at 2 hours. (B) The lesion
became more prominent and moved slightly upward at 7 hours. (C) At 24 hours, prominent curvilinear tracer activity was seen at
the lower part and left side of the abdomen.
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and vomiting. There were signs of peritonitis on physical
examination. The relevant laboratory investigation was as
follows: white blood cell count Z 3.4/mm3 (normal Z
3.9e10.7); lymphocyte Z 1.1/mm3 (normal Z 1.2e3.4);
normal renal function; albumin Z 25 g/L (normal Z
29e42); globulin Z 29 g/L (normal, no reference). An
urgent CT scan of the abdomen revealed free intraperito-
neal gas, a markedly dilated terminal ileum, gross mural
thickening and mucosal enhancement along the terminal
ileum down to the transverse colon. Multiple intra-
abdominal lymphadenopathy was detected. An explor-
atory laparotomy, which was carried out immediately
afterwards, revealed there was a partially concealed
perforation over the terminal ileum, with dense adhesion at
the right side of the abdomen extending down to the right
fallopian tube and a moderate amount of turbid peritonealfluid. A limited right hemicolectomy with double barrel
stoma (ileostomy and colostomy) was performed. The post-
operative course was uneventful, and the previous anti-
tuberculous regimen was restarted 1 week afterwards.
Histological examination of the resected segment of the
terminal ileum revealed there were several ill-formed
granulomas with numerous acid-fast bacilli in the submu-
cosa and subserosa accompanied with transmural inflam-
mation and multiple mucosal erosions. Caseating necrosis
was not present. The peritoneal fluid did not reveal any
viable mycobacterial growth.
A total of 18 months of anti-tuberculous therapy
(6 months of oral INH, pyrazinamide, ethambutol, plus
intravenous amikacin and levofloxacin, followed by 12
months of oral INH, pyrazinamide, ethambutol and moxi-
floxacin) was given to the patient. The closure of the stoma
with ileocolonic anastomosis was performed 3 months after
Figure 2. (A) The ileocecal valve with nodularity. (B) High power field shows inflammatory infiltrates including neutrophils,
lymphocytes and aggregates of histiocytes forming vague granulomas. (C) Ziehl Neelsen stain shows the presence of acid-fast bacilli
(red stained).
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The patient remained well with no evidence of recurrent
MTB in the past 5 years.Discussion
Our patient had intestinal tuberculosis with wide dissemi-
nation into the respiratory and urinary system, which was
complicated with delayed free perforation during anti-
tuberculous treatment. Although the patient did not have
any recurrent sepsis in the past, there are several features
suggesting a probable underlying primary immunodefi-
ciency. The lymphocyte count on admission was extremely
low and there were no cell-mediated immune responses
(i.e., absence of lymphadenopathy and granulomaTable 1 Determination of mitogen-stimulated cytokine prolife
Stimulant IFN-g IL-2
P Normal range P Normal range P N
PHA 680 450e3500 3400 3000e6900 48,800 1
ConA 3400 2000e10,900 1360 1300e6500 47,200
ConA Z concanavalin A; P Z patient; PHA Z phytohemagglutinin.
Results are given as cytokine secreting cells per million peripheral blformation) in the CT scan and pathological specimens.
Patients with primary immunodeficiency diseases usually
present clinically with an increased frequency, severity or
persistence of infections, or occurrence of opportunistic
infections in which our patient belonged to the first cate-
gory. 1 Cells of normal immune systems respond to patho-
gens by producing a variety of cytokines and our patient
showed the defective IL-12 production in the mitogen-
stimulation test.1
IL-12 is a heterodimeric cytokine which consists of two
disulfide-linked subunits, p40 and p35, and is produced by
activated antigen presenting cells (dendritic cells, macro-
phages), particularly upon infection with intracellular
pathogens such as mycobacteria and salmonella.2e7 IL-12
promotes the development and activity of cytotoxic
T-lymphocytes, natural killer cells, and macrophages.8e10 Itby using the patient’s peripheral blood mononuclear cells
IL-6 TNF-a IL-12
ormal range P Normal range P Normal range
9,000e105,000 73,800 27,000e108,000 35 144e1072
19,000e97,000 73,800 19,000e97,000 10 79e558
ood mononuclear cells.
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natural killer (NK) cells.2, 3,8e10 Both IL-12 and IFN-g appear
to be essential for the development of protective cell-
mediated immunity in human. Defects in the IL-12-IFN-g
circuit will increase the susceptibility of individuals to
infections caused by intracellular pathogens, like poorly
pathogenic mycobacteria [non-tuberculous mycobacteria
(NTM)] and salmonella species; these patients have subse-
quently been classified as part of the syndrome Mendelian
susceptibility to mycobacterial disease (MSMD).11 IL-12
deficiency can be a risk factor for acquisition of severe
mycobacterial and salmonella infection, as reported by de
Jong et al.12 In fact, the IL-12-IFN-g circuit is essential for
controlling resistance to these pathogens and no other
redundant protective immune mechanism can compensate
for this deficiency.13
Germlinemutations infivegenes involved in the IL-12-IFN-
g circuit have been found in genetic analysis of affected
kindreds:14 (1) IFNgR1 and IFNgR2, encoding the ligand-
binding chain R1 and R2 of the IFN-g receptor, respectively.
These first two categories comprise partial or complete
recessive null mutations of the receptor signaling chains for
IFN-g. This causes either a defect in receptor expression or
formation of non-functional receptors; (2) STAT1, encoding
the signal transducer and activator of transcription-1 (stat-1)
in IFN-g receptor signaling pathway. Stat-1 is a downstream
signaling molecule for IFN-g. This category comprises partial
or complete defects in the signal transduction molecule
STAT1, which is required for signaling via the IFN-g
receptor;15 (3) IL-12B, encoding the p40 subunit shared by IL-
12 and IL-23. This type of defect results in an inability to
produce IL-12 and IL-23, due to deletion within the gene
encoding the inducible chain of IL-12 (IL-12B), which is
shared by the two cytokines, IL-12 and IL-23;16 (4) IL-12 RB1,
encoding the b1 subunit shared by IL-12 and IL-23 receptors.
This last category is the null recessive mutation of the IL-12
RB1 gene encoding the IL-12 receptor chain; this results in
an inability to respond to IL-12 and IL-23.12, 17
The various types of mutations in these five genes may
be associated with partial or complete deficiency of the
gene product and thus define up to 10 distinct inherited
disorders.13 The severity of the clinical phenotype depends
on the genotype. Complete IFNgR1 and IFNgR2 deficiencies
predispose patients to overwhelming infections with
impaired granuloma formation in early childhood, whereas
partial IFNgR1, IFNgR2 and STAT-1 deficiencies and
complete IL-12 p40 and IL-12Rb1 deficiencies predispose
patients to curable infections with mature granulomas at
various ages. Although the technique of genetic sequencing
is not available in our institution, the overwhelming clinical
course of our patient was compatible to the former entity.
Moreover, our patient did not develop fulminant sepsis with
other viral, bacterial or fungal pathogens, which suggests
that IL-12 may be dispensable for protection to pathogens
other than intracellular bacteria. There are anecdotal
reports of the beneficial effects of IFN-g supplementation
in patients with IL-12B, IL-12Rb1, and dominant partial IFN-
g deficiency.16, 17 IFN-g is of no use in complete IFNgR1 or
-R2 deficiency, where the outcome is poor despite anti-
mycobacterial chemotherapy.
Free intestinal perforation is a rare but serious compli-
cation of intestinal TB, with the reported incidence rangingfrom 1 to 15%.18e20 It may be solitary or multiple and usually
happens in the distal ileum, whichmay be due to its common
involvement in gastrointestinal TB. There are two kinds of
perforation as related to the institution of anti-tuberculous
treatment: early and delay type.21e25 The former occurs
shortly after the initiation of anti-tuberculous therapy and
thus it may represent the natural progression of the disease
process or the impaired ulcer healing and reduced rein-
forcement of mesentery caused by a reduced inflammatory
response, as a result of anti-tuberculous treatment.19 The
other type of perforation is a paradoxical response, as these
patients usually feature with clear documentation of initial
improvement with anti-tuberculous treatment before the
occurrence of intestinal perforation, like our case.22 The
pathogenesis of this phenomenon is not fully understood.
Possible mechanisms include a regain of the host’s delayed
hypersensitivity response, and an increased exposure to
mycobacterial antigens released from killed bacilli.26
Although anti-tuberculous therapy had been interrupted
for a short period and the anti-tuberculous regimen had
a borderline low dose of INH without rifampicin, the clinical
improvement of our patient was accompanied BY a rise of
serum albumin level and lymphocyte count, and supported
the diagnosis of paradoxical response rather than treatment
failure. Previous studies reported that the perforation
occurred between 2 days and 4 months after the initiation of
anti-tuberculous therapy.21e23, 25 Our patient developed
paradoxical deterioration with intestinal perforation about
6.1 months after the initiation of anti-tuberculous therapy.
Cheng et al reported that this paradoxical response occurred
after an upsurge in the lymphocyte count and sometimes an
exaggerated tuberculin skin reactionmightbeobserved.27, 28
Our patient had severe lymphopenia and had a delayed
recovery of her lymphocyte count, which accounted for the
longer delay of the intestinal perforation. The treatment of
choice for perforation in intestinal TB is resection of the
affected segment of the bowel, followed by an end-to-end
anastomosis.24, 25 Simple closure of the lesion is not
advised, as it is associated with a high incidence of leakage
and fistula formation.24, 25 Previous studies reported a high
mortality ranging from25 to 100%. 19, 24, 25 Factors associated
with mortality included delayed operation, multiple perfo-
ration sites, primary closure of the lesions, leakage from the
operation site and steroid therapy. Anti-tuberculous therapy
should be started as soon as possible.
This case highlights the importance of finding any immu-
nodeficiency in those with tuberculosis or NTM infection in
a disseminated, fatal or sometimes in a familial distribution,
and the need to maintain a high index of suspicion of intes-
tinal perforation when patients present with acute abdom-
inal pain while receiving treatment for TB.
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